SG11201509647WA - Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity - Google Patents

Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity

Info

Publication number
SG11201509647WA
SG11201509647WA SG11201509647WA SG11201509647WA SG11201509647WA SG 11201509647W A SG11201509647W A SG 11201509647WA SG 11201509647W A SG11201509647W A SG 11201509647WA SG 11201509647W A SG11201509647W A SG 11201509647WA SG 11201509647W A SG11201509647W A SG 11201509647WA
Authority
SG
Singapore
Prior art keywords
polypeptides
amino acid
acid sequence
reduced immunogenicity
modified bacteriophage
Prior art date
Application number
SG11201509647WA
Other languages
English (en)
Inventor
Richard A Fisher
Robert George Edward Holgate
Francis Joseph Carr
Timothy David Jones
Original Assignee
Neurophage Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurophage Pharmaceuticals Inc filed Critical Neurophage Pharmaceuticals Inc
Publication of SG11201509647WA publication Critical patent/SG11201509647WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
SG11201509647WA 2013-05-28 2014-05-28 Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity SG11201509647WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361828004P 2013-05-28 2013-05-28
US201361828497P 2013-05-29 2013-05-29
PCT/US2014/039760 WO2014193935A1 (fr) 2013-05-28 2014-05-28 Polypeptides comprenant une séquence d'acides aminés modifiée de la protéine g3p d'un bactériophage présentant une immunogénicité réduite

Publications (1)

Publication Number Publication Date
SG11201509647WA true SG11201509647WA (en) 2015-12-30

Family

ID=51168338

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509647WA SG11201509647WA (en) 2013-05-28 2014-05-28 Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity

Country Status (13)

Country Link
US (2) US9988444B2 (fr)
EP (1) EP3003349B1 (fr)
JP (1) JP2016526044A (fr)
KR (1) KR20160010618A (fr)
CN (1) CN105473153A (fr)
AU (1) AU2014274253B2 (fr)
CA (1) CA2913414A1 (fr)
EA (1) EA030389B1 (fr)
HK (1) HK1223285A1 (fr)
MX (1) MX2015016263A (fr)
PH (1) PH12015502585A1 (fr)
SG (1) SG11201509647WA (fr)
WO (1) WO2014193935A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093414A (zh) 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
LT2906235T (lt) 2012-10-02 2017-10-25 Proclara Biosciences, Inc. Bakteriofago sulietų baltymų p3, kaip amiloido rišamųjų agentų, naudojimas
ES2910017T3 (es) 2014-12-03 2022-05-11 Proclara Biosciences Inc Polipéptidos que comprenden una secuencia de aminoácidos modificada de g3p de bacteriófago que carece de una señal de glicosilación
CN107384960B (zh) * 2017-07-25 2020-06-12 吉优诺（上海）基因科技有限公司 基于复制缺陷性重组腺病毒携带il-17结合分子转基因载体及其构建方法和应用
BR112020025111A2 (pt) 2018-06-15 2021-04-06 Proclara Biosciences, Inc. Motivo de interação amiloide geral (gaim)
EP3966227A1 (fr) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions et méthodes d'augmentation vectorisée de la destruction, de l'expression et/ou de la régulation de protéines
CN114057858B (zh) * 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
WO2024119183A1 (fr) 2022-12-02 2024-06-06 Alzheon, Inc. Méthodes de traitement de troubles neurodégénératifs avec du tramiprosate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP1132471A3 (fr) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag Protéines liant le TNF
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
JP3068301B2 (ja) * 1992-01-08 2000-07-24 三菱電機株式会社 Ｉｃカード内のコネクタ支持固定機構
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ES2252732T3 (es) 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
EP1051432B1 (fr) 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
WO2002066514A2 (fr) 2001-02-19 2002-08-29 Merck Patent Gmbh Proteines artificielles presentant une immunogenicite reduite
KR20030082962A (ko) 2001-03-08 2003-10-23 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ)
DE10238846A1 (de) 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
PT1853285E (pt) * 2005-02-01 2011-06-06 Univ Ramot Método para tratamento de inflamação associada a depósitos de amilóide e inflamação cerebral envolvendo microglia activada
JP2009529320A (ja) 2006-02-15 2009-08-20 ラモット・アット・テルアビブ・ユニバーシティ 脳への送達のための抗体および免疫複合体のバインダーとしてのプロテインａをディスプレイする繊維状バクテリオファージ
EP1991259B1 (fr) 2006-02-15 2012-10-10 Ramot at Tel-Aviv University Ltd. Véhicules d'affichage de virus pour traiter la sclérose en plaques
WO2007109733A2 (fr) 2006-03-21 2007-09-27 The Johns Hopkins University Marqueurs de diagnostic et de pronostic et strategies de traitement de la sclerose en plaques
WO2007114139A1 (fr) 2006-04-06 2007-10-11 Fumiaki Uchiyama Expression phagique par un nouveau bactériophage filamenteux
CN101553567A (zh) 2006-07-21 2009-10-07 台拉维夫大学拉莫特 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法
SG10201502661SA (en) 2006-10-11 2015-05-28 Antitope Ltd T cell epitope databases
EP2303315A1 (fr) 2008-05-22 2011-04-06 Ramot at Tel Aviv University Ltd. Procédé de traitement de maladie caractérisée par une plaque
KR20110091778A (ko) 2008-11-24 2011-08-12 라모트 앳 텔-아비브 유니버시티 리미티드 사상 박테리오파지를 이용하는 파킨슨병의 치료방법
WO2011084714A2 (fr) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. Molécules de scfv anti-tnf-alpha stabilisées ou molécules de scfv anti-tweak stabilisées et utilisations associées
JP2014509514A (ja) 2011-03-11 2014-04-21 ラモット アット テルアヴィブ ユニヴァーシティ リミテッド 神経変性タウオパシーを治療するための方法
CN104093414A (zh) * 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
LT2906235T (lt) * 2012-10-02 2017-10-25 Proclara Biosciences, Inc. Bakteriofago sulietų baltymų p3, kaip amiloido rišamųjų agentų, naudojimas
ES2910017T3 (es) 2014-12-03 2022-05-11 Proclara Biosciences Inc Polipéptidos que comprenden una secuencia de aminoácidos modificada de g3p de bacteriófago que carece de una señal de glicosilación

Also Published As

Publication number Publication date
CA2913414A1 (fr) 2014-12-04
CN105473153A (zh) 2016-04-06
EA201592272A1 (ru) 2016-04-29
EP3003349B1 (fr) 2018-12-12
EP3003349A1 (fr) 2016-04-13
US20180251534A1 (en) 2018-09-06
JP2016526044A (ja) 2016-09-01
US9988444B2 (en) 2018-06-05
KR20160010618A (ko) 2016-01-27
AU2014274253A1 (en) 2016-01-21
HK1223285A1 (zh) 2017-07-28
EA030389B1 (ru) 2018-07-31
US20160115223A1 (en) 2016-04-28
PH12015502585A1 (en) 2016-02-29
AU2014274253B2 (en) 2018-06-14
MX2015016263A (es) 2016-04-18
US20170129945A9 (en) 2017-05-11
WO2014193935A1 (fr) 2014-12-04

Similar Documents

Publication Publication Date Title
HK1223285A1 (zh) 包含具有減小的免疫原性的經修飾的噬菌體 氨基酸序列的多肽
HK1203820A1 (en) Fusion polypeptides comprising mucin-domain polypeptide linkers
IL252426A0 (en) Polypeptides containing a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
HK1220492A1 (zh) 重組多肽生產
HRP20180452T1 (hr) Peptidi
HUE054423T2 (hu) Fúziós polipeptidek és vakcinák
HRP20171385T1 (hr) Kombinacije s peptidom s cikliziranom okosnicom
EP2956160A4 (fr) Polypeptides sécréteurs d'insuline
PL3004146T3 (pl) Polipeptydy z aktywnością permeazy
HK1207866A1 (en) Combinations with a backbone-cyclized peptide
GB201315130D0 (en) Peptides
GB201316660D0 (en) Peptides
GB201300529D0 (en) Recombinant polypeptide
GB201300381D0 (en) Peptides